Opthea Ltd. | Income Statement

Fiscal year is July-June. All values AUD Thousands.
2014
2015
2016
2017
2018
Cost of Goods Sold (COGS) incl. D&A
604.20
38.60
30.80
26.60
28.70
Gross Income
604.20
38.60
30.80
26.60
28.70
SG&A Expense
6,922.70
9,345.90
8,054.20
9,869.30
29,880.50
EBIT
7,603.90
9,384.50
8,085.00
9,895.90
29,909.10
Unusual Expense
507.20
-
895.80
-
-
Non Operating Income/Expense
987.10
840.10
443.80
34.90
11.90
Pretax Income
6,849.00
8,121.30
8,101.00
9,360.80
28,919.50
Income Tax
2,859.40
2,720.30
1,569.20
3,167.90
12,017.20
Consolidated Net Income
3,989.60
5,401.00
6,531.80
6,192.90
16,902.20
Net Income
3,996.10
5,312.10
6,507.40
6,192.90
16,902.20
Net Income After Extraordinaries
3,996.10
5,312.10
6,507.40
6,192.90
16,902.20
Net Income Available to Common
3,996.10
5,312.10
6,507.40
6,192.90
16,902.20
EPS (Basic)
0.08
0.05
0.04
0.04
0.08
Basic Shares Outstanding
49,755.30
109,093.30
150,197.20
161,229.00
201,580.60
EPS (Diluted)
0.08
0.05
0.04
0.04
0.08
Diluted Shares Outstanding
49,755.30
109,093.30
150,197.20
161,229.00
201,580.60
EBITDA
7,565.70
9,345.90
8,054.20
9,869.30
29,880.50
Other Operating Expense
76.90
-
-
-
-
Non-Operating Interest Income
274.90
423.10
436.00
500.20
1,001.50
Minority Interest Expense
6.50
88.90
24.40
-
-

About Opthea

View Profile
Address
650 Chapel Street
South Yarra Victoria (VIC) 3141
Australia
Employees -
Website http://www.opthea.com
Updated 07/08/2019
Opthea Ltd. is engaged in developing biological therapeutics for cancer and other serious diseases. It is a biologics drug developer building on its significant intellectual property portfolio around Vascular Endothelial Growth Factor C and D angiogenic molecules and R3. The company focuses on vascular endothelial growth factors to develop truly novel therapies to extend and improve the lives of cancer sufferers.